Business Insider

Radius Health Reports First Quarter 2017 Financial and Operating Results

Radius’ marketing authorisation application (MAA) to the European Medicines Agency (EMA) for the treatment of postmenopausal women with osteoporosis is currently undergoing regulatory review, and we ...
Business Insider

Radius Health Reports Second Quarter 2017 Financial and Operating Results and Provides Business Update

2Q’17 financial results reflect the first 4 weeks of TYMLOS sales in the U.S. Managed care contracts in place for coverage of over 130 million lives for TYMLOS™ (68% of all Commercial and 28% of ...
Nasdaq

Radius Health (RDUS) Earnings Miss in Q3, Tymlos in Focus

Radius Health, Inc. RDUS posted a loss of $1.31 per share in the third quarter of 2017, wider than the loss of $1.07 per share in the year-ago quarter and the Zacks Consensus Estimate loss of $1.24.
Nasdaq

Radius (RDUS) Enrols First Patient in Breast Cancer Study

Radius Health, Inc.RDUS announced that the first patient has been enroled in the phase I study on pipeline candidate, RAD140. RAD140 is a nonsteroidal selective androgen receptor modulator (SARM) ...